Study shows
Lexiva is comparable to Kaletra

A new study released this week by GlaxoSmithKline and Vertex Pharmaceuticals shows that their HIV protease inhibitor Lexiva, when boosted with Norvir, is comparable to Abbott Laboratories' Kaletra, one of the most widely used anti-HIV medications in developed nations. Kaletra already includes a booster dose of Norvir in the same pill with its other active ingredient lopinavir. The study showed that 73% of HIV patients taking Norvir-boosted Lexiva suppressed HIV levels after 48 weeks of treatment. Seventy-one percent of study subjects taking Kaletra had suppressed virus at 48 weeks. All of the study subjects were also taking Ziagen and Epivir during the study. (The Advocate)